A Model for Integration and Interlinking of Idea Management Systems

This paper introduces the use of Semantic Web technologies for the Idea Management Systems as a gap closer between heterogeneous software and achieving interoperability. We present a model that proposes how and what kind of rich metadata annotations to apply in the domain of Idea Management Systems. In addition, as a part of our model, we present a Generic Idea and Innovation Management Ontology (GI2MO). The described model is backed by a set of use cases followed by evaluations that prove how Semantic Web can work as tool to create new opportunities and leverage the contemporary Idea Management legacy systems into the next level

Toward an internally consistent astronomical distance scale

Accurate astronomical distance determination is crucial for all fields in astrophysics, from Galactic to cosmological scales. Despite, or perhaps because of, significant efforts to determine accurate distances, using a wide range of methods, tracers, and techniques, an internally consistent astronomical distance framework has not yet been established. We review current efforts to homogenize the Local Group's distance framework, with particular emphasis on the potential of RR Lyrae stars as distance indicators, and attempt to extend this in an internally consistent manner to cosmological distances. Calibration based on Type Ia supernovae and distance determinations based on gravitational lensing represent particularly promising approaches. We provide a positive outlook to improvements to the status quo expected from future surveys, missions, and facilities. Astronomical distance determination has clearly reached maturity and near-consistency.Comment: Review article, 59 pages (4 figures); Space Science Reviews, in press (chapter 8 of a special collection resulting from the May 2016 ISSI-BJ workshop on Astronomical Distance Determination in the Space Age

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Synthesis and inhibitory activities at mGluRs of 3-alkylated and N-alkylated cyclopentyl-glutamate analogues

The conformationally restricted glutamate analogues, 3-alkyl-1-amino-2-cyclopentene-1,3-dicarboxylates and N-alkylated analogues have been prepared in a regioselective and diastereoselective manner. From the biological studies of the 3-alkylated analogues, compound 13b was found to be the most potent antagonist (IC50 7.7 μM) at mGluR2. Amongst the N-alkylated analogues, compound 20 was found to be a partial agonist (EC50 9.5 μM) and as well as an antagonist (IC50 47 μM) at mGluR2

Intra- and interchromosomal contact mapping reveals the Igh locus has extensive conformational heterogeneity and interacts with B-lineage genes

We thank Philipp Voigt for critical reading of the manuscript; Hashem Koohy, Jonathan Cairns, Peter Chovanec, and Bhupinder Virk for assistance with bioinformatics; Kristina Tabbada for assistance with sequencing; and Simon Walker for assistance with microscopy. We are grateful to Rudi Hendriks, Erasmus MC, Rotterdam for providing the Rag81X mouse strain. O.M. (1426107) and C.R. (1947339) were supported by PhD studentships from the Medical Research Council, UK. S.J.C. was supported by an Investigator Grant (Leadership, GNT1198014) awarded by the National Health and Medical Research Council (NHMRC). Research in L.G.'s lab was funded by the Novartis Foundation, the European Research Council (grant no. 759366, BioMeTre), Marie Skłodowska-Curie Innovative Training Networks (grant nos. 813327 ChromDesign and 813282 PEP-NET) under the European Union's Horizon 2020 Research and Innovation Program, and the Swiss National Science Foundation (grant no. 310030_192642). Research in A.E.C.'s laboratory was supported by grants from the Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0404, BBS/E/B/000C0405, BBS/E/B/000C0427, BBS/E/B/000C0428). The Babraham Institute provides funds, through the BBSRC, for open access publication fees.We thank Philipp Voigt for critical reading of the manuscript; Hashem Koohy, Jonathan Cairns, Peter Chovanec, and Bhupinder Virk for assistance with bioinformatics; Kristina Tabbada for assistance with sequencing; and Simon Walker for assistance with microscopy. We are grateful to Rudi Hendriks, Erasmus MC, Rotterdam for providing the Rag81X mouse strain. O.M. (1426107) and C.R. (1947339) were supported by PhD studentships from the Medical Research Council, UK. S.J.C. was supported by an Investigator Grant (Leadership, GNT1198014) awarded by the National Health and Medical Research Council (NHMRC). Research in L.G.'s lab was funded by the Novartis Foundation, the European Research Council (grant no. 759366, BioMeTre), Marie Skłodowska-Curie Innovative Training Networks (grant nos. 813327 ChromDesign and 813282 PEP-NET) under the European Union's Horizon 2020 Research and Innovation Program, and the Swiss National Science Foundation (grant no. 310030_192642). Research in A.E.C.'s laboratory was supported by grants from the Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0404, BBS/E/B/000C0405, BBS/E/B/000C0427, BBS/E/B/000C0428). The Babraham Institute provides funds, through the BBSRC, for open access publication fees. M.J.T.S. S.S. S.J.C. and A.E.C. conceptualized the study. S.S. M.J.T.S. and D.J.B. devised the method. O.M. C.H.R. L.S.M. B.M.J. M.J.T.S. and D.J.B. performed experiments. Y.Z. performed modeling. O.M. C.H.R. Y.Z. L.S.M. S.W.W. A.S.-P. F.K. S.A. and C.V. analyzed data. P.F. L.G. and A.E.C. secured funding and supervised research. O.M. C.H.R. L.S.M. and A.E.C. wrote the manuscript with input from all other authors. P.F. and S.S. are co-founders and shareholders of Enhanc3D Genomics Ltd. We worked to ensure sex balance in the selection of non-human subjects. We worked to ensure diversity in experimental samples through the selection of the genomic datasets. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. We support inclusive, diverse, and equitable conduct of research.To produce a diverse antibody repertoire, immunoglobulin heavy-chain (Igh) loci undergo large-scale alterations in structure to facilitate juxtaposition and recombination of spatially separated variable (V), diversity (D), and joining (J) genes. These chromosomal alterations are poorly understood. Uncovering their patterns shows how chromosome dynamics underpins antibody diversity. Using tiled Capture Hi-C, we produce a comprehensive map of chromatin interactions throughout the 2.8-Mb Igh locus in progenitor B cells. We find that the Igh locus folds into semi-rigid subdomains and undergoes flexible looping of the V genes to its 3' end, reconciling two views of locus organization. Deconvolution of single Igh locus conformations using polymer simulations identifies thousands of different structures. This heterogeneity may underpin the diversity of V(D)J recombination events. All three immunoglobulin loci also participate in a highly specific, developmentally regulated network of interchromosomal interactions with genes encoding B cell-lineage factors. This suggests a model of interchromosomal coordination of B cell development